United Therapeutics Trading Volume Plummets 50.81% to 406th Position Despite Ralinepag Phase 3 Trial Optimism

On June 23, 2025, United Therapeutics (UTHR) experienced a significant decline in trading volume, with a total of $208 million in shares traded, marking a 50.81% decrease from the previous day. This placed United Therapeutics at the 406th position in terms of trading volume for the day. The stock price also decreased by 1.49%, marking the second consecutive day of decline, with a total decrease of 1.82% over the past two days.

United Therapeutics has recently concluded the enrollment for the ADVANCE OUTCOMES study, which is focused on the treatment of pulmonary arterial hypertension (PAH) using ralinepag. This drug is being developed as a potential once-daily oral prostacyclin agonist for PAH patients. The completion of this enrollment is a critical step in addressing the unmet needs in PAH treatment, as it allows for the continued accrual of clinical worsening events through the end of 2025.

Ralinepag has previously shown positive results in a phase 2 study involving 61 PAH participants, demonstrating a significant reduction in median pulmonary vascular resistance. This success in the phase 2 study has paved the way for the ongoing phase 3 trial, which aims to further validate the drug's efficacy and safety profile. The positive outcomes from the phase 2 study have generated optimism among investors and analysts, who see the potential for ralinepag to become a groundbreaking treatment option for PAH patients.